NeuroPace (NASDAQ:NPCE) reported fourth-quarter and full-year 2025 results that management said reflected sustained momentum in its core RNS business, improving margins, and continued progress toward ...

NeuroPace, Inc. ( NPCE) Q4 2025 Earnings Call March 3, 2026 4:30 PM EST Good afternoon, and welcome to NeuroPace Fourth Quarter 2025 Conference Call. As a reminder, this call is being recorded.

Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, ...

Detailed price information for Jazz Pharma Plc (JAZZ-Q) from The Globe and Mail including charting and trades.

Home security video shows a woman ringing the doorbell at Ashley Hogue’s home before walking away with a package containing ...

The company reiterated "full year 2026 revenue guidance of $98 million to $100 million," assuming "underlying core RNS growth of 20% to 22% within our current adult focal epilepsy indication and ...

Joel Becker, NeuroPace, Inc. Chief Executive Officer, who will summarize our recent performance and strategic progress, followed by a detailed financial review and outlook from Patrick Williams, our ...

Next week, researchers, clinicians, industry leaders, and families will gather at the 2026 MDA Clinical & Scientific Conference, hosted by the Muscular Dystrophy Association (MDA), to discuss the ...